What is Dexrabeprazole Sodium & Cinitapride Capsules used For ?
Pharmaceutical Product Monograph: Dexrabeprazole Sodium + Cinitapride Capsules
In the pharmaceutical industry, this combination represents a high-tier Chiral PPI + Third-Generation Prokinetic therapy. As a pharmacist and manufacturer, I classify this as a “Superior Motility Solution”—it is technically designed for patients with Refractory GERD (reflux that doesn’t respond to standard meds) and Functional Dyspepsia.
At your WHO-GMP facility in Mumbai, this FDC (Fixed-Dose Combination) is a specialized Gastroenterology SKU that offers significant advantages over older combinations like Rabeprazole + Domperidone.
Therapeutic Profile: Primary Indications
This combination is indicated for the treatment of gastrointestinal disorders where both acid suppression and enhanced movement (motility) are required.
| Indication | Clinical Context | Technical Rationale |
| Non-Erosive Reflux (NERD) | Acid Reflux | Treats patients who have classic heartburn symptoms but no visible damage on endoscopy. |
| Functional Dyspepsia | Indigestion | Relieves the “early fullness,” bloating, and upper abdominal heaviness after meals. |
| Delayed Gastric Emptying | Motility Disorder | Specifically targets the stomach’s inability to move food into the small intestine efficiently. |
| Chronic Gastritis | Inflammation | Reduces acid irritation while preventing the “backwash” of bile into the stomach. |
Mechanism: The “Chiral & Prokinetic” Synergy
This combination works through two highly sophisticated chemical pathways:
Dexrabeprazole (The S-Isomer PPI): As we discussed, this is the “active half” of Rabeprazole. It technically blocks the $H^+/K^+\text{-ATPase}$ pump (the proton pump) in the stomach. Because it is a chiral molecule, 10 mg of Dexrabeprazole is as effective as 20 mg of regular Rabeprazole, providing potent acid control with a lower chemical load on the liver.
Cinitapride (The 5-HT Receptor Modulator): Unlike Domperidone (which is a dopamine antagonist), Cinitapride is a 5-HT4 agonist and 5-HT2 antagonist. It technically stimulates the release of acetylcholine in the gut, which significantly speeds up gastric emptying and improves the coordination of the digestive tract.
The Result: Dexrabeprazole stops the “acid fire,” while Cinitapride ensures the “stomach traffic” moves in the right direction (downward), preventing reflux from happening in the first place.
The Pharmacist’s “Technical Warning”
The “30-Minute” Rule: To work effectively, this capsule must be taken on an empty stomach, ideally 30 minutes before breakfast. This gives the Cinitapride time to activate the gut’s motility before food arrives.
Safety over Domperidone: One major technical benefit of Cinitapride is that it has a lower risk of cardiac side effects (QT prolongation) and hormonal issues (prolactin increase) compared to Domperidone.
Avoid Alcohol: Alcohol can increase gastric irritation and counteract the prokinetic effect of Cinitapride.
Neurological Monitoring: While rare, Cinitapride can occasionally cause minor tremors or “extrapyramidal symptoms” in very sensitive patients.
The Manufacturer’s Perspective: Technical & Export
From the CEO’s desk at Healthy Life Pharma / Healthy Inc:
The “Premium FDC” USP: On your digital marketplace, highlight this as an “Advanced Second-Line Therapy.” It is more expensive than standard PPI combinations, making it a high-value item for private hospital chains and gastroenterology clinics.
Pelletization Quality: Cinitapride is often included as Extended Release (ER) pellets within the capsule. Ensure your Mumbai facility’s coating process is precise to maintain a steady release of the prokinetic over 12–24 hours.
Stability: Dexrabeprazole is highly sensitive to moisture and acid. Use Alu-Alu blister packaging to ensure the enteric coating of the pellets remains intact until it reaches the patient’s intestine.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Dexrabeprazole + Cinitapride to support your registration in international B2B markets.